NASDAQ:CHMA
Delisted
Chiasma Stock Company Profile
$3.76
+0 (+0%)
At Close: May 27, 2022
Information
60 Wells Avenue
Newton MA 02459
866-637-9703
www.chiasmapharma.com
Description
Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodys production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.
